Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
luvometinib + cytarabine
- Development stage
- Unknown
- Lead developer
- Fosun Pharma
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
Luvometinib + cytarabine is an investigational combination regimen being evaluated for the treatment of Langerhans cell histiocytosis (LCH). Luvometinib (FCN-159) is a potent and selective small-molecule inhibitor of MEK1 and MEK2, which are key kinases in the MAPK/ERK signaling pathway. This pathway is frequently dysregulated in histiocytic neoplasms, often due to mutations such as BRAF V600E. Cytarabine is a pyrimidine nucleoside analog that acts as an antimetabolite, interfering with DNA synthesis by inhibiting DNA polymerase and incorporating into DNA strands. The combination is currently being studied in a response-adapted Phase 2 clinical trial sponsored by Shanghai Ninth People's Hospital. In this study, patients receive luvometinib induction, and cytarabine is added for those who do not achieve a complete metabolic response, aiming to improve objective response rates in patients with LCH requiring systemic therapy.
- Other names
- luvometinib plus cytarabineFCN-159 plus cytarabineFCN159 plus cytarabineFCN 159 plus cytarabine
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)DNA polymerase familyDNAMEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on luvometinib + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on luvometinib + cytarabine.